Expression of the neutral amino acids transporter ASCT1 in esophageal carcinomas.
Cancers cells utilize more glucose and amino acids than their benign counterparts. Overexpression of the facilitative glucose transporter Glut1 in human cancers was found to correlate with aggressive biologic behavior. The aim of this work was to determine whether the neutral amino acid transporter ASCT1 is expressed in human esophageal carcinomas, and to correlate the findings with Glut1 expression. Sections of formalin-fixed and paraffin-embedded tissue from 42 cases of esophageal carcinomas were entered in the study. Immunohistochemical staining was performed using a rabbit anti-ASCT1 IgG developed in our laboratory, and anti-Glut1 antibody, using standard avidin-streptavidine immunoperoxidase method. Sections of formalin-fixed and paraffin-embedded HepG2 cells were used as positive controls. The percent of ASCT1-positive cells was scored. Statistical analysis was performed using Fisher's exact test. ASCT1 immunoreactivity was cytoplasmic, whereas Glut1 was membranous. Significantly more adenocarcinomas expressed ASCT1 than squamous cell carcinomas (p < 0.0001), whereas Glut1 expression was similar in both tumor types. There was no association between the expression of either transporter and lymph node metastasis. Glut1 was expressed more often in the better differentiated than the poorly differentiated squamous carcinomas (p = 0.003). These results suggest that unlike in squamous cell carcinoma, ASCT1 plays a significant role in the recruitment of amino acids in adenocarcinoma of the esophagus, and suggest that the metabolic needs, and uptake of nutrients, are regulated differently in these two tumor types. Additional studies with larger number of patients are needed to determine the biological significance of ASCT1 expression in esophageal carcinomas.
Younes
M
M
Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Pathak
M
M
Finnie
D
D
Sifers
R N
RN
Liu
Y
Y
Schwartz
M R
MR
D000230:Adenocarcinoma / Q000473:pathology*; D026905:Amino Acid Transport Systems; D000596:Amino Acids / Q000378:metabolism; D000818:Animals; D000906:Antibodies; D001692:Biological Transport; D006528:Carcinoma, Hepatocellular / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D002352:Carrier Proteins / Q000032:analysis*; D004938:Esophageal Neoplasms / Q000473:pathology*; D051272:Glucose Transporter Type 1; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000473:pathology; D009004:Monosaccharide Transport Proteins / Q000032:analysis; D011817:Rabbits; D014407:Tumor Cells, Cultured
D026905:Amino Acid Transport Systems; D000596:Amino Acids; D000906:Antibodies; D002352:Carrier Proteins; D051272:Glucose Transporter Type 1; D009004:Monosaccharide Transport Proteins; C495677:SLC2A1 protein, human